Neutropenic sepsis on day 9 of adjuvant TC chemotherapy
A 62-year-old woman with a pT2 pN1 (1/14 nodes), ER-positive, HER2-negative breast cancer started adjuvant docetaxel 75 mg/m² plus cyclophosphamide 600 mg/m² (TC) three weeks after surgery. She has no significant comorbidity, no central venous access device, and takes no regular medication apart from occasional paracetamol. On day 9 of cycle 1 she presents to the emergency department with rigors and a temperature of 38.9 °C and says she feels 'fluey'. Observations: BP 92/58 mmHg, HR 118/min, RR 22/min, SpO2 94% on air, GCS 15. She has grade 1 oral mucositis, no diarrhoea, no skin or line source, and clear lung fields on examination. Bloods: haemoglobin 98 g/L, WBC 0.4 ×10⁹/L, neutrophils 0.2 ×10⁹/L, platelets 88 ×10⁹/L, creatinine 96 µmol/L, lactate 3.4 mmol/L, CRP 180 mg/L. Chest radiograph and urinalysis are unremarkable.
1. What is your immediate management in the first hour, and which findings drive the decision about where she should be treated?
Read the worked answer
Recognise the syndrome first. A single temperature ≥38.3 °C with neutrophils 0.2 ×10⁹/L is febrile neutropenia, and the BP 92/58 mmHg, HR 118/min and lactate 3.4 mmol/L make this sepsis rather than a low-risk febrile neutropenia episode.
First hour - treatment and investigation run in parallel:
- Two sets of blood cultures (at least one peripheral), urine culture, throat swab, and stool culture if diarrhoea develops; send lactate, FBC, U&E, LFT, CRP and a chest radiograph. Do not wait for any result before giving antibiotics.
- Intravenous crystalloid 30 mL/kg for the hypotension, with reassessment after each bolus.
- Start an anti-pseudomonadal β-lactam within 60 minutes: piperacillin–tazobactam 4.5 g q6h, or cefepime 2 g q8h, or meropenem 1 g q8h if there is recent ESBL exposure or the local resistance pattern warrants it.
- Vancomycin is not routine: it is indicated for suspected line infection, skin/soft-tissue infection, pneumonia, or MRSA colonisation with haemodynamic instability - none of which are present here.
- If she remains hypotensive after fluids, add an aminoglycoside and escalate cover for resistant Gram-negatives, and involve senior and critical care teams early; noradrenaline if MAP stays below 65 mmHg.
- G-CSF is not a treatment for sepsis and must not delay antibiotics.
Disposition is decided by risk, not by the neutrophil count. Hypotension, lactate >2 mmol/L and an anticipated prolonged neutropenia after docetaxel make her high risk, so she needs admission for intravenous therapy and monitoring, irrespective of a MASCC score.
2. What features would have made outpatient management of febrile neutropenia appropriate, and how would that have changed your plan?
Read the worked answer
Outpatient management is reserved for patients who are genuinely low risk, and the assessment must be made at presentation, not retrospectively.
Features that would have permitted it here:
- No hypotension (systolic BP ≥90 mmHg), no tachycardia-driven hypoperfusion, and a normal lactate.
- No organ dysfunction - normal creatinine, liver function and oxygen saturation.
- An expected neutropenia duration of less than 7 days. TC commonly causes neutropenia of about 5–7 days, but this cannot be assumed after a first cycle and needs to be weighed with the clinical picture.
- No comorbidity (cardiac, renal, hepatic, diabetes with poor control), ECOG 0–1, and no indwelling central line.
- No mucositis beyond grade 1, no pneumonia, no abdominal pain or diarrhoea, and no prior fungal infection.
- A reliable patient and carer, a working telephone, and the ability to return to hospital within 60 minutes.
What would change: she would receive oral ciprofloxacin plus amoxicillin–clavulanate (or levofloxacin monotherapy according to local policy), with the first dose given in the department, observation for at least 4 hours, and review within 24 hours. Explicit return advice and a written safety-net plan are mandatory. In this case the hypotension and raised lactate mean she is high risk regardless of any score, so admission and intravenous antibiotics are required.
3. She recovers and is discharged on day 5. What is your plan for the remaining adjuvant chemotherapy, and why?
Read the worked answer
Febrile neutropenia is a sentinel event; repeating the same dose and schedule without modification is unsafe.
- Confirm the aim of treatment. This is adjuvant therapy for node-positive breast cancer, so dose intensity matters, but the absolute benefit of docetaxel must be weighed against a potentially fatal complication. The discussion should be documented and shared with the patient.
- Secondary G-CSF prophylaxis is indicated. The FN risk of TC exceeds 20% and she has already had a documented event. Give pegfilgrastim 6 mg on day 2, or daily filgrastim, with every subsequent cycle.
- Modify the cytotoxic dose. Reducing docetaxel to 60 mg/m² (a 20% reduction) is acceptable and does not materially compromise adjuvant benefit. An alternative is to switch to a regimen with lower febrile neutropenia risk, such as an anthracycline–cyclophosphamide sequence or weekly paclitaxel, particularly if neutropenia was prolonged.
- Reassess before cycle 2. Require ANC >1.0 ×10⁹/L and platelets >100 ×10⁹/L, review mucositis, and check that the patient understands when to return.
- Do not omit G-CSF in later cycles simply because the count has recovered. Document the plan, the risk–benefit discussion, and the patient's consent to continue.